DNAGinkgo Bioworks Holdings, Inc.
$11.34-23% 1Y
$11.34
$5.4852 weeks$16.09
DNA in its own filings
DNA's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
149
Events found in the filings · across 1,561 filings · the record starts in 2020
- Hard flags
- 3
Hard flags
- Most recent filing
- Aug 6, 2026
Most recent filing · Form 10-Q
- Record starts
- Nov 25, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountant2 occurrences
- 2024-03-14
- Late periodic report2 occurrences
- 2023-03-01
- Delisting notice / listing-rule failure3 occurrences
- 2024-09-04
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2024-09-12
- SEC comment-letter activity39 occurrences
- 2025-08-12
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland.Earnings release · press release
- May 7, 2026Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab.Earnings release · press release
- Apr 7, 2026On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”) completed the previously announced transaction (the “Transaction”) with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchaser”) pursuant to the Stock Purchase …Acquisition or disposition completed · Form 8-K
- Feb 27, 2026On February 26, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the “Company”), entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Tower Biosecurity, Inc. (the “Purchaser”) and Ginkgo Biosecurity, LLC (“Biosecurity”)Material agreement entered · Form 8-K
- Feb 26, 2026Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business.Earnings release · press release
- Dec 23, 2025On December 18, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) announced that Dr. Reshma Shetty, the Company’s President, Chief Operating Officer, and member of the Board of Directors, will transition her Chief Operating Officer duties to Jennifer Wipf and Dr. Jason Kelly, the Company’s Chief Executive Officer …Director or officer change · Form 8-K
- Nov 6, 2025Ginkgo Bioworks Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Sep 4, 2025On September 4, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Allen & Company LLC (“Allen”), who is acting as the sales agent (the “Agent”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…